P. Lamy

发表

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

J. Cherrington, M. D. Miller, N. Hellmann, 1998, Antimicrobial Agents and Chemotherapy.

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

J. Kahn, P. Barditch-Crovo, A. Collier, 2001, Antimicrobial Agents and Chemotherapy.

Amplification techniques and diagnosis of prion diseases.

J. Laplanche, S. Haïk, N. Privat, 2019, Revue neurologique.

Mitoxantrone/Cytarabine with or without Quinine as a Potential MDR- Reversing Agent for the Treatment of Acute Leukemias

E. Solary, P. Moreau, N. Ifrah, 1996 .

Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy

P. Griffiths, J. Cherrington, V. Emery, 1999, Journal of medical virology.

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.

J. Cherrington, A. Collier, S. Deeks, 1997, The Journal of infectious diseases.

Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

J. Cherrington, T. Cihlar, M. D. Miller, 1998, Molecular pharmacology.

In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.

J. Cherrington, J. Lalezari, W. Drew, 1998, The Journal of infectious diseases.

Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants

E. Schiff, T. Wright, E. Yoshida, 2000, Hepatology.

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.

C. Gibbs, T. Howard, G. Singer, 1999, Transplantation.

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

S. Bloor, G. Alexander, D. Wight, 2001, Gut.

Adefovir and Tenofovir Susceptibilities of HIV‐1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS‐96‐408

J. Cherrington, A. Mulato, N. Margot, 2001, Journal of acquired immune deficiency syndromes.

In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA

M. Wainberg, H. Salomón, J. Cherrington, 1998, Antiviral therapy.

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.

J. Cherrington, M. D. Miller, A. Mulato, 1999, The Journal of infectious diseases.

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

J. Cherrington, A. Mulato, N. Margot, 2001 .

Early Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques

N. Pedersen, J. Cherrington, K. V. Van Rompay, 1999, Journal of Virology.

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

Christine Hogan, Alan S Perelson, A. Perelson, 2003, AIDS.

9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA

N. Pedersen, J. Cherrington, K. V. Van Rompay, 1999, Antimicrobial Agents and Chemotherapy.